Zdrowie i gospodarka · 06/12/2022
FDA Releases Final Guidance on Alternative Dosing Regimens for PD-1/PD-L1 Blocking Antibodies
The FDA has released a final guidance for industry on the use of pharmacokinetic-based criteria to support alternative dosing regimens for PD-1/PD-L1 blocking antibodies, which will aid in the approval of these treatments for cancer patients.
Source: Federal Register — Food and Drug AdministrationOpen original release →